Implementation of management guidelines for chronic myeloidl leukemia perspectives in the United States

P and T

Volumn 37, Issue 11, 2012, Pages 640-648

  Rizzieri, David ^a   Moore, Joseph O ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Duke Raleigh Hospital   (United States)

Author keywords

Chronic myeloid leukemia; Clinical practice guidelines; Dasatinib; Imatinib; Nilotinib; Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EYELID EDEMA; FATIGUE; FLUID RETENTION; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEADACHE; HEALTH CARE QUALITY; HEALTH ECONOMICS; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PATHOPHYSIOLOGY; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRACTICE GUIDELINE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84870697761     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112(13):4808-4817.
2. Vardiman JW. Chronic myelogenous leukemia, BCR-ABL1+. Am J Clin Pathol 2009;132(2):250-260.
3. Danielson E, DeMartino J, Mullen JA. Managed care and medical oncology: The focus is on value. JNCCN J Natl Compr Cancer Network 2010;3:S28-S37.
4. Quintas-Cardama A, Flamm M, Lill M, et al. Resource utilization and perceptions of major molecular response in chronic myeloid leukemia (CML): Results of a Delphi panel study (Abstract). Value Health 2011;14(3):A157.
5. Pasquini R, Cortes JE, Kantarjian HM, et al. Survey of the frontline treatment and management of chronic myeloid leukemia (CML) in a real-word setting: Third annual update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (the WORLD CML Registry). Presented at the American Society of Hematology annual meeting, San Diego, December 10, 2011. Available at: https://ash.confex.com/ash/2011/webprogram/Paper40024.html. Accessed June 14, 2012.
6. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-2417.
7. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110(10):3540-3546.
8. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362(24):2260-2270.
9. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007;109(12):5143-5150.
10. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004.
11. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362(24):2251-2259.
12. Baccarani M, Castagnetti F, Gugliotta G, et al. Response definitions and European LeukemiaNet management recommendations. Best Pract Res Clin Haematol 2009;22(3):331-341.
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2.2012. Available at: www.nccn.org/professionals/physician_gls/PDF/cml.pdf. Accessed July 5, 2011.
14. National Comprehensive Cancer Network. About NCCN. Available at: www.nccn.org/about/default.asp. Accessed March 22, 2011.
15. European LeukemiaNet. Available at: www.leukemia-net.org/content/home. Accessed March 22 2011.
16. Pelz AF, Kroning H, Franke A, et al. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements. Ann Hematol 2002;81(3):147-153.
17. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases. Leukemia 2002;16(1):53-59.
18. Talpaz M, Kantarjian HM, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314(17):1065-1069.
19. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 1995;345(8962):1392-1397.
20. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330(12):820-825.
21. Mauro MJ, Druker BJ. STI571: Targeting BCR-ABL as therapy for CML. Oncologist 2001;6(3):233-238.
22. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349(15):1423-1432.
23. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65(11):4500-4505.
24. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7(2):129-141.
25. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12(9):841-851.
26. Hughes TP, Hochhaus A, Saglio G, et al. ENESTnd update: Continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) (Abstract). Blood 2010;116(21):207.
27. Larson RA, Kim D, Rosti G, et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month followup (Abstract). J Clin Oncol 2011;29:6511.
28. Saglio G, LeCoutre PD, Pasquini R, et al. Nilotinib versus imatinib in patients (pts) with newly diagnosed Philadelphia chromosome- positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 36-month (mo) follow-up (Abstract). Blood 2011;118(21):452.
29. Shah N, Kantarjian H, Hochhaus A, et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up (Abstract). Blood 2010;116(21):206.
30. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119(5):1123-1129.
31. Shah NP, Kim D-W, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response, or intolerance to imatinib. Haematologica 2010;95(2):232-240.
32. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117(4):1141-1145.
33. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109(6):2303-2309.
34. Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118(5):1208-1215.
35. Soverini S, Gnani A, De Benedittis C, et al. Validation of the new European LeukemiaNet (ELN) recommendations for Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia: An analysis of the GIMEMA CML Working Party studies (Abstract). Blood 2011;118(21):112.
36. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerabilityadapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-a in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29(12):1634-1642.
37. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the international randomized study of interferon versus STI571 (IRIS). Blood 2010;116(19):3758-3765.
38. Müller MC, Hochhaus A, Lauseker M, et al. Molecular response<1% BCR-ABL IS at 12 months is associated with improved overall and progression-free survival: The randomized German CML Study IV (Abstract). Blood 2010;116(21):669.
39. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 2009;113(22):5401-5411.
40. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28(14):2381-2388.
41. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. Blood 2011;117(14):3733-3376.
42. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25(6):481-496.
43. Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010;26(1):61-69.
44. Kim DH, Sriharsha L, Jung CW, et al. Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: Which parameter at which time-point does matter? Am JHematol 2010;85(11):856-862.
45. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26(9):2096-2102.
46. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30(3):232-238.
47. Hochhaus A, Saglio G, Chuah C, et al. Dasatinib and imatinibinduced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Analysis of molecular response kinetics in the DASISION trial (Abstract). Blood 2011;118(21):2767.
48. Latagliata R, Breccia M, Carmosino I, et al. Complete cytogenetic response after 3 months is a very early indicator of good response to imatinib as first-line treatment in chronic myelogenous leukemia (Abstract). Blood 2011;118(21):3783.
49. Ohm A-C, Barbany G, Arvidsson I, et al. Landmark analysis of imatinib treatment in CML chronic phase: ES-FISH <10% Ph+ at 3 months associated with better cytogenetic response and improved long-term event-free survival (Abstract). Blood 2011;118(21):1702.
50. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24(10):1719-1724.
51. Goh HG, Lin M, Fukushima T, et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma 2011;52(5):896-904.
52. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11(11):1029-1035.
53. Mahon F-X, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: Updated results of the STIM study (Abstract). Blood 2011;118(21):603.
54. Rea D, Rousselot P, Nicolini FE, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable Bcr-Abl transcripts: Results from the French CML Group (FILMC) (Abstract). Blood 2011;118(21):604.
55. Goh H-G, Choi S-Y, Bang J-H, et al. Discontinuation of imatinib therapy in chronic myeloid leukemia patients with sustained complete molecular response4.5 (CMR4.5) (Abstract). Blood 2011; 118(21):2763.
56. Matsuki E, Ono Y, Sakurai M, et al. Discontinuation of imatinib in patients with CML and sustained complete molecular response (CMR) for over 2 years in the Japanese population: An interim analysis of KEIO STIM study (Abstract). Blood 2011;118(21):3765.
57. Rousselot P, Makhoul PC, Rea D, et al. Fluctuating values of molecular residual disease (MRD) without molecular progression after imatinib discontinuation in patients (pts) with chronic myeloid leukemia (CML) who have maintained complete molecular response: Implications for re-treatment criteria and role of prior interferon therapy: A pilot study of the French CML Group (FILMC) (Abstract). Blood 2011;118(21):3781.
58. Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia (Abstract). Blood 2011;118(21):3759.
59. Benson AB, Brown E. Role of NCCN in integrating cancer clinical practice guidelines into the healthcare debate. Am Health Drug Benefits 2008;1(1):28-33.
60. Hoyle M, Rogers G, Moxham T, et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health 2011;14(8):1057-1067.
61. Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26(12):2861-2869.
62. Stephens J, Carpiuc KT, Botteman M. The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis. Int J Gen Med 2010;3:31-36.